| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.014 | 0.8 |